HAIXI PHARMA secures NMPA IND approval for next-generation glioblastoma candidate HXP089

Bulletin Express07-14

Fujian Haixi Pharmaceuticals Co., Ltd. (HAIXI PHARMA) has received Investigational New Drug (IND) approval from China’s National Medical Products Administration (NMPA) for HXP089, a selective multi-target small-molecule therapy for glioblastoma.

HXP089 becomes HAIXI PHARMA’s third proprietary program to advance into clinical trials, following oncology asset C019199 and ophthalmology candidate HXP056. Discovered via the company’s MultiSel-Opt platform, HXP089 is engineered to modulate several disease-relevant pathways while demonstrating strong blood-brain barrier penetration—features aimed at improving outcomes in glioblastoma, where current treatment options of surgery and chemoradiotherapy are hindered by high recurrence rates and limited post-relapse therapies.

The NMPA clearance enables clinical studies to assess HXP089’s safety, tolerability and preliminary efficacy in glioblastoma patients. Management highlighted the milestone as further validation of the MultiSel-Opt platform’s capability to generate differentiated small-molecule assets.

Shareholders and potential investors are advised to exercise caution when dealing in HAIXI PHARMA shares and to seek professional advice if in doubt.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1142109509?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-14 17:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1142109509","market":"us","top_or_hot":-1,"title":"HAIXI PHARMA secures NMPA IND approval for next-generation glioblastoma candidate HXP089","media":"Bulletin Express","content":"<p>Fujian Haixi Pharmaceuticals Co., Ltd. (HAIXI PHARMA) has received Investigational New Drug (IND) approval from China’s National Medical Products Administration (NMPA) for HXP089, a selective multi-target small-molecule therapy for glioblastoma.</p>\n<p>HXP089 becomes HAIXI PHARMA’s third proprietary program to advance into clinical trials, following oncology asset C019199 and ophthalmology candidate HXP056. Discovered via the company’s MultiSel-Opt platform, HXP089 is engineered to modulate several disease-relevant pathways while demonstrating strong blood-brain barrier penetration—features aimed at improving outcomes in glioblastoma, where current treatment options of surgery and chemoradiotherapy are hindered by high recurrence rates and limited post-relapse therapies.</p>\n<p>The NMPA clearance enables clinical studies to assess HXP089’s safety, tolerability and preliminary efficacy in glioblastoma patients. Management highlighted the milestone as further validation of the MultiSel-Opt platform’s capability to generate differentiated small-molecule assets.</p>\n<p>Shareholders and potential investors are advised to exercise caution when dealing in HAIXI PHARMA shares and to seek professional advice if in doubt.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HAIXI PHARMA secures NMPA IND approval for next-generation glioblastoma candidate HXP089</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHAIXI PHARMA secures NMPA IND approval for next-generation glioblastoma candidate HXP089\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-14 17:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Fujian Haixi Pharmaceuticals Co., Ltd. (HAIXI PHARMA) has received Investigational New Drug (IND) approval from China’s National Medical Products Administration (NMPA) for HXP089, a selective multi-target small-molecule therapy for glioblastoma.</p>\n<p>HXP089 becomes HAIXI PHARMA’s third proprietary program to advance into clinical trials, following oncology asset C019199 and ophthalmology candidate HXP056. Discovered via the company’s MultiSel-Opt platform, HXP089 is engineered to modulate several disease-relevant pathways while demonstrating strong blood-brain barrier penetration—features aimed at improving outcomes in glioblastoma, where current treatment options of surgery and chemoradiotherapy are hindered by high recurrence rates and limited post-relapse therapies.</p>\n<p>The NMPA clearance enables clinical studies to assess HXP089’s safety, tolerability and preliminary efficacy in glioblastoma patients. Management highlighted the milestone as further validation of the MultiSel-Opt platform’s capability to generate differentiated small-molecule assets.</p>\n<p>Shareholders and potential investors are advised to exercise caution when dealing in HAIXI PHARMA shares and to seek professional advice if in doubt.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02637","symbol_name":"海西新药","start_time":0,"source_url":"","article_id":"1142109509","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1142109509","pubTimestamp":1784020849,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Fujian Haixi Pharmaceuticals Co., Ltd. (HAIXI PHARMA) has received Investigational New Drug (IND) approval from China’s National Medical Products Administration (NMPA) for HXP089, a selective...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02637":"海西新药"},"translate_title":"海西药业下一代胶质母细胞瘤候选药物HXP089获得NMPA IND批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02637":1},"content_text":"Fujian Haixi Pharmaceuticals Co., Ltd. (HAIXI PHARMA) has received Investigational New Drug (IND) approval from China’s National Medical Products Administration (NMPA) for HXP089, a selective multi-target small-molecule therapy for glioblastoma.\nHXP089 becomes HAIXI PHARMA’s third proprietary program to advance into clinical trials, following oncology asset C019199 and ophthalmology candidate HXP056. Discovered via the company’s MultiSel-Opt platform, HXP089 is engineered to modulate several disease-relevant pathways while demonstrating strong blood-brain barrier penetration—features aimed at improving outcomes in glioblastoma, where current treatment options of surgery and chemoradiotherapy are hindered by high recurrence rates and limited post-relapse therapies.\nThe NMPA clearance enables clinical studies to assess HXP089’s safety, tolerability and preliminary efficacy in glioblastoma patients. Management highlighted the milestone as further validation of the MultiSel-Opt platform’s capability to generate differentiated small-molecule assets.\nShareholders and potential investors are advised to exercise caution when dealing in HAIXI PHARMA shares and to seek professional advice if in doubt.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1142109509","isCrawlerRequest":true}